We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+19.79%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$121M
Cap. Flow
+$99.3M
Cap. Flow %
27.73%
Top 10 Hldgs %
55.61%
Holding
85
New
30
Increased
11
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.12M
4
SWTX
SpringWorks Therapeutics
SWTX
+$5.02M
5
AZN icon
AstraZeneca
AZN
+$4.12M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.61M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.98M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.69M
4
RPTX
Repare Therapeutics
RPTX
+$4.49M
5
KURA icon
Kura Oncology
KURA
+$3.89M

Sector Composition

Rank Sector Weight
1 Healthcare 51.05%
2 Financials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$89.3M 24.92%
+250,000
New +$99.3M
ESTA icon
2
Establishment Labs
ESTA
$2.72B
$17.8M 4.98%
326,668
-33,288
-9% -$1.99M
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$16M 4.47%
813,998
-123,570
-13% -$2.48M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.9M 3.61%
+190,000
New +$10.5M
IWM icon
5
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$11.5M 3.22%
+70,000
New +$12.8M
SNY icon
6
Sanofi
SNY
$107B
$11.4M 3.18%
+300,000
New +$13.4M
ASND icon
7
Ascendis Pharma A/S
ASND
$17.1B
$10.3M 2.88%
100,000
-25,087
-20% -$2.38M
SNY icon
8
PUT
Sanofi
SNY
$107B
$9.51M 2.65%
+250,000
New +$11.1M
KURA icon
9
Kura Oncology
KURA
$964M
$9.23M 2.58%
675,753
-252,503
-27% -$3.89M
LNTH icon
10
Lantheus
LNTH
$7B
$9.14M 2.55%
130,000
-10,000
-7% -$757K
NARI
11
DELISTED
Inari Medical, Inc. Common Stock
NARI
$8.72M 2.43%
120,000
-102,173
-46% -$7.61M
AZN icon
12
AstraZeneca
AZN
$262B
$8.23M 2.3%
75,000
+32,500
+76% +$4.12M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.8B
$6.5M 1.81%
100,000
– –
VTYX
14
DELISTED
Ventyx Biosciences
VTYX
$5.93M 1.66%
+170,000
New +$3.76M
PNT
15
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.77M 1.61%
746,576
+720,998
+2,819% +$6.12M
AZN icon
16
PUT
AstraZeneca
AZN
$262B
$5.48M 1.53%
+50,000
New +$6.34M
BLU
17
DELISTED
BELLUS Health Inc.
BLU
$5M 1.4%
473,597
-19,681
-4% -$209K
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$4.99M 1.39%
+175,000
New +$5.02M
MDGL icon
19
PUT
Madrigal Pharmaceuticals
MDGL
$12.8B
$4.87M 1.36%
+75,000
New +$5.21M
PEN icon
20
CALL
Penumbra
PEN
$12.5B
$4.74M 1.32%
+25,000
New +$4.01M
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
$4.52M 1.26%
1,290,511
-81,733
-6% -$294K
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$376M
$4.27M 1.19%
267,794
+17,328
+7% +$270K
MORF
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.15M 1.16%
146,491
-69,232
-32% -$1.93M
ACLX
24
DELISTED
Arcellx
ACLX
$3.94M 1.1%
210,138
+135,138
+180% +$2.59M
ZNTL icon
25
Zentalis Pharmaceuticals
ZNTL
$364M
$3.68M 1.03%
170,000
+100,000
+143% +$2.73M
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Affinity Asset Advisors held 85 positions worth $358M, up 51% from $237M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Affinity Asset Advisors deployed $99.3M of net new capital in Q3 2022, opening 30 new positions and adding to 11 existing holdings. Its largest new stake was Sanofi: 300,000 shares worth $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 64% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $7.61M trimmed.

  • Affinity Asset Advisors's largest Q3 2022 buy was Sanofi: 300,000 shares worth $11.4M.
  • Affinity Asset Advisors added most to POINT Biopharma Global Inc. Common Stock in Q3 2022, an estimated $6.12M increase.
  • Affinity Asset Advisors's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $7.61M.
  • Affinity Asset Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $5.98M.
  • Affinity Asset Advisors's ten largest holdings make up 56% of its $358M portfolio in Q3 2022.
  • Affinity Asset Advisors opened 30 new positions and closed 21 in Q3 2022.
  • Affinity Asset Advisors's portfolio value rose 51% quarter-over-quarter to $358M.

Based on Affinity Asset Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.